Actinium Pharmaceuticals Inc. (Delaware) (ATNM) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Actinium Pharmaceuticals Inc. (Delaware) (NYSE: ATNM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $1.43 (-3.38% 1D, market cap $46.5M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ATNM ranks #413 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ATNM carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BMEA (Biomea Fusion Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $46.4M) and MREO (Mereo BioPharma Group plc) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $46.2M). Among the 5-stock peer group, ATNM leads on earnings multiple (N/A) while ATNM leads on capital efficiency (-35.0% ROIC).
Per ATNM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001388320), Actinium Pharmaceuticals Inc. (Delaware) generated $90.0K in revenue (-99.9% YoY), -$33.9M in net income, and -$24.7M in free cash flow against $51.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 70% of 52W Range • RSI-14 at 59.7 (BULLISH MOMENTUM)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While ATNM currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.21) and Max Pain ($1.50) forces dealer call-delta covering toward $1.81.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Actinium Pharmaceuticals Inc. (Delaware) (ATNM) dropped -3.38% to $1.43, trading at 70% of its 52-week range ($0.74 – $1.72). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced that an abstract highl
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced an inducement equity award to a newly hired non-executive emplo
Gainers Axogen (NASDAQ:AXGN) stock rose 17.7% to $44.1 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q3 earnings report came out today.
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced that the first‑in‑huma
First‑in‑human Phase 1 study evaluates HER3‑targeted ATNM‑400 in metastatic castration‑resistant prostate cancer population, including patients with and without prior PSMA‑directed therapy HER3‑targeted alpha
Actinium Pharmaceuticals shares jump 9% after positive Phase 1 ATNM-400 trial results in prostate cancer show early safety and retention.
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced encouraging initial cl
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced new preclinical result
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced new preclinical results
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -99.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ATNM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ATNM. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Actinium Pharmaceuticals Inc. (Delaware) (ATNM) ranks #413 by composite RQD confidence (43/100, grade D-) and #755 by equity capitalization ($46.5M). Within this direct 5-issuer industry benchmark cohort, ATNM leads on earnings valuation at N/A trailing P/E, while ATNM leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ATNM currently leads its immediate peer cohort in composite quantitative strength at 43/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ATNM
ACTIVE
Actinium Pharmaceuticals Inc. (Delaware) | D- | 43/100 | — | — | -35.0% | -3.38% | $46.5M | Benchmark Subject |
| BMEA Biomea Fusion Inc. | E | 30/100 | — | — | -35.0% | +3.19% | $46.4M | /bmea-vs-atnm → |
| MREO Mereo BioPharma Group plc | D- | 37/100 | — | — | -35.0% | +0.17% | $46.2M | /mreo-vs-atnm → |
| ELTX Elicio Therapeutics Inc. | E | 28/100 | — | — | -35.0% | -5.36% | $45.5M | /eltx-vs-atnm → |
| HOWL Werewolf Therapeutics Inc. | D- | 42/100 | — | — | -35.0% | +6.48% | $47.9M | /howl-vs-atnm → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Actinium Pharmaceuticals Inc. (Delaware) (ATNM) reported GAAP revenue of $90.0K (-99.9% vs. FY2024 revenue of $117.9M , and +11.1% cumulative change since FY2023) , GAAP net income of -$33.9M, operating cash flow of -$24.6M, and free cash flow of -$24.7M (+25.4% YoY). On the balance sheet, ATNM closed FY2025 with $51.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $90.0K | -$33.9M | -$24.6M | -$24.7M | $51.8M | — |
| FY2024 (FY) | 2024-12-31 | $117.9M | -$38.2M | -$33.1M | -$33.1M | $76.9M | — |
| FY2023 (FY) | 2023-12-31 | $81.0K | -$48.8M | -$47.3M | -$47.3M | — | — |
As of 2026-11-03, Actinium Pharmaceuticals Inc. (Delaware) (NYSE: ATNM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $1.43 (-3.38% 1D, market cap $46.5M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ATNM ranks #413 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ATNM carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BMEA (Biomea Fusion Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $46.4M) and MREO (Mereo BioPharma Group plc) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $46.2M). Among the 5-stock peer group, ATNM leads on earnings multiple (N/A) while ATNM leads on capital efficiency (-35.0% ROIC).
Per ATNM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001388320), Actinium Pharmaceuticals Inc. (Delaware) generated $90.0K in revenue (-99.9% YoY), -$33.9M in net income, and -$24.7M in free cash flow against $51.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
ATNM last traded at $1.43 (-3.38% on volume of 104,586 shares), positioning the stock +18.18% above its 50-day simple moving average ($1.21) and +27.68% above its 200-day simple moving average ($1.12). Across its 52-week range of $0.74 to $1.72, ATNM sits at the 70.4% percentile with a 14-day RSI of 59.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($1.25 to $1.61).
Actinium Pharmaceuticals Inc. (Delaware) (ATNM) earns a live Roarable RQD composite score of 43/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $1.43 (-3.38% 1D, market capitalization $46.5M).
Actinium Pharmaceuticals Inc. (Delaware) (ATNM) is a NYSE-listed issuer. It operates in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. Reported revenue appears in the SEC financials at $0.1M for FY 2025 and — for FY 2024, which indicates minimal commercial revenue in the periods provided.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Actinium Pharmaceuticals Inc. (Delaware) (ATNM) reported $90.0K in annual revenue (up from $117.9M in FY2024, -99.9% YoY) and -$33.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($81.0K revenue, -$48.8M net income) through FY2025, ATNM scaled operating cash flow to -$24.6M and free cash flow to -$24.7M, backed by $51.8M in total assets against $0 in total debt.
Sector classification is Health Care and industry is Biotechnology: Pharmaceutical Preparations. No upstream or downstream dependencies, sector correlations, or second-order bottlenecks are identified in source data.
Real-time company headlines, analyst actions, and sector developments for Actinium Pharmaceuticals Inc. (Delaware) (ATNM) • Click "Debate This Headline" to argue it in the Roar Pit below
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced that an abstract highl
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced an inducement equity award to a newly hired non-executive emplo
Gainers Axogen (NASDAQ:AXGN) stock rose 17.7% to $44.1 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q3 earnings report came out today.
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced that the first‑in‑huma
First‑in‑human Phase 1 study evaluates HER3‑targeted ATNM‑400 in metastatic castration‑resistant prostate cancer population, including patients with and without prior PSMA‑directed therapy HER3‑targeted alpha
Actinium Pharmaceuticals shares jump 9% after positive Phase 1 ATNM-400 trial results in prostate cancer show early safety and retention.
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced encouraging initial cl
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced new preclinical result
The street is overcomplicating Actinium Pharmaceuticals Inc. (Delaware) (ATNM). Institutional accumulation and options positioning score 14/20, the strongest pillar in the RQD rating.. With an RQD score of 43/100 (D-) and Forensic Balance Sheet at 8/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.60.
@RiskArb_Desk Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
Negative ROIC of -35% and 0% FCF yield, with FY 2025 free cash flow of -$24.7M, show the company is not self-funding.. Look at the math on ATNM: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $1.30 before getting long.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: